Literature DB >> 28562677

Correction: Helios expression and Foxp3 TSDR methylation of IFNy+ and IFNy- Treg from kidney transplant recipients with good long-term graft function.

Karina Trojan, Christian Unterrainer, Rolf Weimer, Nuray Bulut, Christian Morath, Mostafa Aly, Li Zhu, Gerhard Opelz, Volker Daniel.   

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0173773.].

Entities:  

Year:  2017        PMID: 28562677      PMCID: PMC5451083          DOI: 10.1371/journal.pone.0179069

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Fig 4 is incorrect. The authors have provided a corrected version here.
Fig 4

Methylation status of CD4+CD25+CD127-IFNγ+ Treg in transplant patients and healthy controls.

Approximately, half of male kidney transplant recipients with good long-term stable graft function show mainly methylated (>75% Foxp3 TSDR methylation) IFNy+ Treg in the blood whereas the other half of male patients possess in addition a sizeable proportion of demethylated (11–75% Foxp3 TSDR methylation) IFNy+ Treg suggesting that they possess IFNy+ Treg with transient as well as stable Foxp3 expression.

Methylation status of CD4+CD25+CD127-IFNγ+ Treg in transplant patients and healthy controls.

Approximately, half of male kidney transplant recipients with good long-term stable graft function show mainly methylated (>75% Foxp3 TSDR methylation) IFNy+ Treg in the blood whereas the other half of male patients possess in addition a sizeable proportion of demethylated (11–75% Foxp3 TSDR methylation) IFNy+ Treg suggesting that they possess IFNy+ Treg with transient as well as stable Foxp3 expression.
  1 in total

1.  Helios expression and Foxp3 TSDR methylation of IFNy+ and IFNy- Treg from kidney transplant recipients with good long-term graft function.

Authors:  Karina Trojan; Christian Unterrainer; Rolf Weimer; Nuray Bulut; Christian Morath; Mostafa Aly; Li Zhu; Gerhard Opelz; Volker Daniel
Journal:  PLoS One       Date:  2017-03-15       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.